Search Results - "Duffaud, F"

Pazopanib in advanced vascular sarcomas: an EORTC Soft Tissue and Bone Sarcoma Group (STBSG) retrospective analysis by Kollár, A, Jones, R L, Stacchiotti, S, Gelderblom, H, Guida, M, Grignani, G, Steeghs, N, Safwat, A, Katz, D, Duffaud, F, Sleijfer, S, van der Graaf, W T, Touati, N, Litière, S, Marreaud, S, Gronchi, A, Kasper, B

“…Pazopanib is a multitargeted tyrosine kinase inhibitor approved for the treatment of patients with selective subtypes of advanced soft tissue sarcoma (STS) who…”
Get more information

Final analysis of the randomized trial on imatinib as an adjuvant in localized gastrointestinal stromal tumors (GIST) from the EORTC Soft Tissue and Bone Sarcoma Group (STBSG), the Australasian Gastro-Intestinal Trials Group (AGITG), UNICANCER, French Sarcoma Group (FSG), Italian Sarcoma Group (ISG), and Spanish Group for Research on Sarcomas (GEIS) by Casali, P.G., Le Cesne, A., Velasco, A.P., Kotasek, D., Rutkowski, P., Hohenberger, P., Fumagalli, E., Judson, I.R., Italiano, A., Gelderblom, H., Penel, N., Hartmann, J.T., Duffaud, F., Goldstein, D., Martin-Broto, J., Gronchi, A., Wardelmann, E., Marréaud, S., Zalcberg, J.R., Litière, S., Blay, J.-Y.

“…In 2004, we started an intergroup randomized trial of adjuvant imatinib versus no further therapy after R0-R1 surgery in localized, high/intermediate-risk…”
Get full text

Surgery in reference centers improves survival of sarcoma patients: a nationwide study by Blay, J.-Y., Honoré, C., Stoeckle, E., Meeus, P., Jafari, M., Gouin, F., Anract, P., Ferron, G., Rochwerger, A., Ropars, M., Carrere, S., Marchal, F., Sirveaux, F., Di Marco, A., Le Nail, L.R., Guiramand, J., Vaz, G., Machiavello, J.-C., Marco, O., Causeret, S., Gimbergues, P., Fiorenza, F., Chaigneau, L., Guillemin, F., Guilloit, J.-M., Dujardin, F., Spano, J.-P., Ruzic, J.-C., Michot, A., Soibinet, P., Bompas, E., Chevreau, C., Duffaud, F., Rios, M., Perrin, C., Firmin, N., Bertucci, F., Le Pechoux, C., Le Loarer, F., Collard, O., Karanian-Philippe, M., Brahmi, M., Dufresne, A., Dupré, A., Ducimetière, F., Giraud, A., Pérol, D., Toulmonde, M., Ray-Coquard, I., Italiano, A., Le Cesne, A., Penel, N., Bonvalot, S.

“…NETSARC (netsarc.org) is a network of 26 sarcoma reference centers with specialized multidisciplinary tumor boards (MDTB) aiming to improve the outcome of…”
Get full text

Sporadic desmoid-type fibromatosis: a stepwise approach to a non-metastasising neoplasm—a position paper from the Italian and the French Sarcoma Group by Gronchi, A., Colombo, C., Le Péchoux, C., Dei Tos, A.P., Le Cesne, A., Marrari, A., Penel, N., Grignani, G., Blay, J.Y., Casali, P.G., Stoeckle, E., Gherlinzoni, F., Meeus, P., Mussi, C., Gouin, F., Duffaud, F., Fiore, M., Bonvalot, S.

“…Desmoid-type fibromatosis (DF) is a rare locally aggressive monoclonal proliferation of myofibroblasts lacking metastatic capacity. It may be observed in…”
Get full text

Advanced chondrosarcomas: role of chemotherapy and survival by Italiano, A., Mir, O., Cioffi, A., Palmerini, E., Piperno-Neumann, S., Perrin, C., Chaigneau, L., Penel, N., Duffaud, F., Kurtz, J.E., Collard, O., Bertucci, F., Bompas, E., Le Cesne, A., Maki, R.G., Ray Coquard, I., Blay, J.Y.

“…There are limited data about the role of chemotherapy in patients with advanced chondrosarcomas. The medical charts of 180 patients with advanced…”
Get full text

Prediction of local and metastatic recurrence in solitary fibrous tumor: construction of a risk calculator in a multicenter cohort from the French Sarcoma Group (FSG) database by Salas, S., Resseguier, N., Blay, J.Y., Le Cesne, A., Italiano, A., Chevreau, C., Rosset, P., Isambert, N., Soulie, P., Cupissol, D., Delcambre, C., Bay, J.O., Dubray-Longeras, P., Krengli, M., De Bari, B., Villa, S., Kaanders, J.H.A.M., Torrente, S., Pasquier, D., Thariat, J.O., Myroslav, L., Sole, C.V., Dincbas, H.F., Habboush, J.Y., Zilli, T., Dragan, T., Khanfir, K., Ugurluer, G., Cena, T., Duffaud, F., Penel, N., Bertucci, F., Ranchere-Vince, D., Terrier, P., Bonvalot, S., Macagno, N., Lemoine, C., Lae, M., Coindre, J.M., Bouvier, C.

“…Solitary fibrous tumors (SFT) are rare unusual ubiquitous soft tissue tumors that are presumed to be of fibroblastic differentiation. At present, the challenge…”
Get full text

Metastatic angiosarcomas: doxorubicin-based regimens, weekly paclitaxel and metastasectomy significantly improve the outcome by Penel, N., Italiano, A., Ray-Coquard, I., Chaigneau, L., Delcambre, C., Robin, Y.M., Bui, B., Bertucci, F., Isambert, N., Cupissol, D., Bompas, E., Bay, J.O., Duffaud, F., Guillemet, C., Blay, J.Y.

“…Angiosarcomas are a rare but aggressive form of soft tissue sarcoma. At metastatic stage, the clinical benefit of therapeutic intervention remains debatable…”
Get full text

Activity and safety of crizotinib in patients with advanced clear-cell sarcoma with MET alterations: European Organization for Research and Treatment of Cancer phase II trial 90101 ‘CREATE’ by Schöffski, P., Wozniak, A., Stacchiotti, S., Rutkowski, P., Blay, J.-Y., Lindner, L.H., Strauss, S.J., Anthoney, A., Duffaud, F., Richter, S., Grünwald, V., Leahy, M.G., Reichardt, P., Sufliarsky, J., van der Graaf, W.T., Sciot, R., Debiec-Rychter, M., van Cann, T., Marréaud, S., Lia, M., Raveloarivahy, T., Collette, L., Bauer, S.

“…Clear-cell sarcoma (CCSA) is an orphan malignancy, characterized by a specific t(12;22) translocation, leading to rearrangement of the EWSR1 gene and…”
Get full text

Imatinib for progressive and recurrent aggressive fibromatosis (desmoid tumors): an FNCLCC/French Sarcoma Group phase II trial with a long-term follow-up by Penel, N., Le Cesne, A., Bui, B.N., Perol, D., Brain, E.G., Ray-Coquard, I., Guillemet, C., Chevreau, C., Cupissol, D., Chabaud, S., Jimenez, M., Duffaud, F., Piperno-Neumann, S., Mignot, L., Blay, J.-Y.

“…Imatinib evaluated as a new treatment option in patients with recurrent or established progressive aggressive fibromatosis/desmoid tumor (AF/DT). Forty…”
Get full text

High incidence of CDA deficiency in patients with hematological malignancies: perspectives and therapeutic implications by Donnette, M., Ciccolini, J., Pissier, C., Costello, R., Duffaud, F., Salas, S., Farnault, L., Tichadou, A., Arcani, R., Jarrot, P.A., Ouafik, L.H., Venton, G., Fanciullino, R.

Get full text

A randomized clinical trial of adjuvant chemotherapy with doxorubicin, ifosfamide, and cisplatin followed by radiotherapy versus radiotherapy alone in patients with localized uterine sarcomas (SARCGYN study). A study of the French Sarcoma Group by Pautier, P., Floquet, A., Gladieff, L., Bompas, E., Ray-Coquard, I., Piperno-Neumann, S., Selle, F., Guillemet, C., Weber, B., Largillier, R., Bertucci, F., Opinel, P., Duffaud, F., Reynaud-Bougnoux, A., Delcambre, C., Isambert, N., Kerbrat, P., Netter-Pinon, G., Pinto, N., Duvillard, P., Haie-Meder, C., Lhommé, C., Rey, A.

“…There is no proven benefit of adjuvant treatment of uterine sarcoma (US). SARCGYN phase III study compared adjuvant polychemotherapy followed by pelvic…”
Get full text

A phase II of gemcitabine combined with pazopanib followed by pazopanib maintenance, as second-line treatment in patients with advanced leiomyosarcomas: A unicancer French Sarcoma Group study (LMS03 study) by Pautier, P., Penel, N., Ray-Coquard, I., Italiano, A., Bompas, E., Delcambre, C., Bay, J.-O., Bertucci, F., Delaye, J., Chevreau, C., Cupissol, D., Bozec, L., Eymard, J.-C., Saada, E., Isambert, N., Guillemet, C., Rios, M., Piperno-Neumann, S., Chenuc, G., Duffaud, F.

“…Options in second-line therapy after doxorubicin-based chemotherapy for metastatic/advanced leiomyosarcoma include gemcitabine (G), trabectedin and pazopanib…”
Get full text

Localized high grade endometrial stromal sarcoma and localized undifferentiated uterine sarcoma: a retrospective series of the French Sarcoma Group by Meurer, Marie, Floquet, A, Ray-Coquard, I, Bertucci, F, Auriche, M, Cordoba, A, Piperno-Neumann, S, Salas, S, Delannes, M, Chevalier, T, Italiano, A, Blay, J Y, Mancini, Julien, Pautier, P, Duffaud, F

“…High grade endometrial stromal sarcoma and undifferentiated uterine sarcomas are associated with a very poor prognosis. Although large surgical resection is…”
Get more information

Advanced well-differentiated/dedifferentiated liposarcomas: role of chemotherapy and survival by Italiano, A., Toulmonde, M., Cioffi, A., Penel, N., Isambert, N., Bompas, E., Duffaud, F., Patrikidou, A., Lortal, B., Le Cesne, A., Blay, J.-Y., Maki, R.G., Schwartz, G.K., Antonescu, C.R., Singer, S., Coindre, J.-M., Bui, B.

“…Data regarding the role of systemic therapy in patients with advanced well-differentiated/dedifferentiated liposarcomas (WDLPS/DDLPS) are limited. From 2000 to…”
Get full text

Epithelioid hemangio-endothelioma (EHE) in NETSARC: The nationwide series of 267 patients over 12 years by Blay, JY, Piperno-Neumann, S., Watson, S., Dufresne, A., Valentin, T., Duffaud, F., Toulmonde, M., Italiano, A., Bertucci, F., Tlemsani, C., Firmin, N., Bompas, E., Perrin, C., Ropars, M., Saada-Bouzid, E., Dubray-Longeras, P., Hervieu, A., Lebbe, C., Gantzer, J., Chaigneau, L., Fiorenza, F., Rios, M., Isambert, N., Soibinet, P., Boudou-Roquette, P., Verret, B., Ferron, G., Ryckewaert, T., Lebellec, L., Brahmi, M., Gouin, F., Meeus, P., Vaz, G., Le Loarer, F., Karanian, M., De Pinieux, G., Ducimetiere, F., Chemin, C., Morelle, M., Le Cesne, A., Penel, N.

“…Epithelioid hemangioendothelioma (EHE) is an ultrarare sarcoma whose natural history and treatment is not well defined. We report on the presentation and…”
Get full text

Surgery in reference centers improves survival of sarcoma patients: a nationwide study by Blay, J -Y, Honoré, C, Stoeckle, E, Meeus, P, Jafari, M, Gouin, F, Anract, P, Ferron, G, Rochwerger, A, Ropars, M, Carrere, S, Marchal, F, Sirveaux, F, Di Marco, A, Le Nail, L R, Guiramand, J, Vaz, G, Machiavello, J -C, Marco, O, Causeret, S, Gimbergues, P, Fiorenza, F, Chaigneau, L, Guillemin, F, Guilloit, J -M, Dujardin, F, Spano, J -P, Ruzic, J -C, Michot, A, Soibinet, P, Bompas, E, Chevreau, C, Duffaud, F, Rios, M, Perrin, C, Firmin, N, Bertucci, F, Le Pechoux, C, Le Loarer, F, Collard, O, Karanian-Philippe, M, Brahmi, M, Dufresne, A, Dupré, A, Ducimetière, F, Giraud, A, Pérol, D, Toulmonde, M, Ray-Coquard, I, Italiano, A, Le Cesne, A, Penel, N, Bonvalot, S

Get full text

Sclerosing Epithelioid Fibrosarcoma (SEF) versus Low Grade Fibromyxoid Sarcoma (LGFMS): Presentation and outcome in the nationwide NETSARC+ series of 330 patients over 13 years by Blay, J Y, Tlemsani, C, Toulmonde, M, Italiano, A, Rios, M, Bompas, E, Valentin, T, Duffaud, F, Le Nail, L R, Watson, S, Firmin, N, Dubray-Longeras, P, Ropars, M, Perrin, C, Hervieu, A, Lebbe, C, Saada-Bouzid, E, Soibinet, P, Fiorenza, F, Bertucci, F, Boudou, P, Vaz, G, Bonvalot, S, Honoré, C, Marec-Berard, P, Minard, V, Cleirec, M, Biau, D, Meeus, P, Babinet, A, Dumaine, V, Carriere, S, Fau, M, Decanter, G, Gouin, F, Ngo, C, Le Loarer, F, Karanian, M, Meurgey, A, Dufresne, A, Brahmi, M, Chemin-Airiau, C, Ducimetiere, F, Penel, N, Le Cesne, A

“…Sclerosing Epithelioid Fibrosarcoma (SEF) and Low Grade Fibromyxoid Sarcoma (LGFMS) are ultrarare sarcomas sharing common translocations whose natural history…”
Get full text

Influence of imatinib interruption and rechallenge on the residual disease in patients with advanced GIST: results of the BFR14 prospective French Sarcoma Group randomised, phase III trial by Patrikidou, A., Chabaud, S., Ray-Coquard, I., Bui, B.N., Adenis, A., Rios, M., Bertucci, F., Duffaud, F., Chevreau, C., Cupissol, D., Domont, J., Pérol, D., Blay, J.Y., Le Cesne, A.

“…We previously demonstrated that interruption of imatinib mesylate (IM) in responding patients (pts) with advanced gastrointestinal stromal tumours (GISTs)…”
Get full text

Advanced soft-tissue sarcoma in elderly patients: patterns of care and survival by Garbay, D., Maki, R.G., Blay, J.Y., Isambert, N., Piperno Neumann, S., Blay, C., Zanardi, E., Boudou-Rouquette, P., Bozec, L., Duffaud, F., Bertucci, F., Italiano, A.

“…There are no data regarding the management of advanced soft-tissue sarcoma (STS) in elderly patients. We retrospectively reviewed the charts of patients ≥75…”
Get full text

GDC-0449 in patients with advanced chondrosarcomas: a French Sarcoma Group/US and French National Cancer Institute Single-Arm Phase II Collaborative Study by Italiano, A., Le Cesne, A., Bellera, C., Piperno-Neumann, S., Duffaud, F., Penel, N., Cassier, P., Domont, J., Takebe, N., Kind, M., Coindre, J.-M., Blay, J.-Y., Bui, B.

“…Pre-clinical data have suggested a therapeutic role of Hedgehog (Hh) pathway inhibitors in chondrosarcoma. This phase II trial included patients with…”
Get full text